Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age : The Copenhagen General Population Study. / Simony, Sofie Bay; Mortensen, Martin Bødtker; Langsted, Anne; Afzal, Shoaib; Kamstrup, Pia Rørbæk; Nordestgaard, Børge Grønne.

I: Atherosclerosis, Bind 355, 08.2022, s. 76-82.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Simony, SB, Mortensen, MB, Langsted, A, Afzal, S, Kamstrup, PR & Nordestgaard, BG 2022, 'Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study', Atherosclerosis, bind 355, s. 76-82. https://doi.org/10.1016/j.atherosclerosis.2022.06.1023

APA

Simony, S. B., Mortensen, M. B., Langsted, A., Afzal, S., Kamstrup, P. R., & Nordestgaard, B. G. (2022). Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis, 355, 76-82. https://doi.org/10.1016/j.atherosclerosis.2022.06.1023

Vancouver

Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis. 2022 aug.;355:76-82. https://doi.org/10.1016/j.atherosclerosis.2022.06.1023

Author

Simony, Sofie Bay ; Mortensen, Martin Bødtker ; Langsted, Anne ; Afzal, Shoaib ; Kamstrup, Pia Rørbæk ; Nordestgaard, Børge Grønne. / Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age : The Copenhagen General Population Study. I: Atherosclerosis. 2022 ; Bind 355. s. 76-82.

Bibtex

@article{652a0de7677c4aab8330e63627109cc7,
title = "Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study",
abstract = "Background and aims: Lipoprotein(a) is a well-known causal risk factor for cardiovascular morbidity and mortality. Little is known about the effect of age and sex on lipoprotein(a) levels, and it is largely unknown if the same elevation in lipoprotein(a) confers the same increase in risk in women and men. We investigated whether lipoprotein(a) levels and lipoprotein(a) associated risks of morbidity and mortality by age are similar in women and men. Methods: We included 37,545 women and 32,497 men from the Copenhagen General Population Study. Results: Plasma lipoprotein(a) increased with age, and in women we found an additional increase around age 50 (age by sex interaction p = 8∙10−7). In women, levels were 27% higher after menopause (p = 4∙10−61) and 12% lower during hormone replacement therapy (p = 2∙10−19). Adjustment for estimated Glomerular Filtration Rate in both sexes and plasma estradiol in women resulted in attenuated sex differences in lipoprotein(a) levels. In sex and age stratified multivariable adjusted models, lipoprotein(a) >40 mg/dL(83 nmol/L) versus <10 mg/dL(18 nmol/L) was associated with increased risk of myocardial infarction, ischemic heart disease, aortic valve stenosis, and heart failure (men only), but not statistically significant with risk of ischemic stroke, cardiovascular mortality, or all-cause mortality. Conclusions: Lipoprotein(a) levels increased modestly around age 50 selectively in women; however, risk of morbidity and mortality for high lipoprotein(a) was similar in women and men above age 50. This implies that elevated lipoprotein(a) above age 50 is a relatively more common cardiovascular risk factor in women, pointing toward repeat measurements in women above age 50.",
keywords = "Cardiovascular disease, Death, Hormone replacement therapy, Lipids, Lipoprotein(a), Sex differences",
author = "Simony, {Sofie Bay} and Mortensen, {Martin B{\o}dtker} and Anne Langsted and Shoaib Afzal and Kamstrup, {Pia R{\o}rb{\ae}k} and Nordestgaard, {B{\o}rge Gr{\o}nne}",
note = "Funding Information: This work was supported by The Danish Heart Foundation [ 19-R134-A9219 ], Copenhagen, Denmark, Beckett Foundation [ 19-2-4567 ], Copenhagen, Denmark, Direkt{\o}r Jacob Madsens og Hustru Olga Madsens fond, Copenhagen, Denmark , and Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark . Neither had any influence on the research conducted. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = aug,
doi = "10.1016/j.atherosclerosis.2022.06.1023",
language = "English",
volume = "355",
pages = "76--82",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age

T2 - The Copenhagen General Population Study

AU - Simony, Sofie Bay

AU - Mortensen, Martin Bødtker

AU - Langsted, Anne

AU - Afzal, Shoaib

AU - Kamstrup, Pia Rørbæk

AU - Nordestgaard, Børge Grønne

N1 - Funding Information: This work was supported by The Danish Heart Foundation [ 19-R134-A9219 ], Copenhagen, Denmark, Beckett Foundation [ 19-2-4567 ], Copenhagen, Denmark, Direktør Jacob Madsens og Hustru Olga Madsens fond, Copenhagen, Denmark , and Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark . Neither had any influence on the research conducted. Publisher Copyright: © 2022 The Authors

PY - 2022/8

Y1 - 2022/8

N2 - Background and aims: Lipoprotein(a) is a well-known causal risk factor for cardiovascular morbidity and mortality. Little is known about the effect of age and sex on lipoprotein(a) levels, and it is largely unknown if the same elevation in lipoprotein(a) confers the same increase in risk in women and men. We investigated whether lipoprotein(a) levels and lipoprotein(a) associated risks of morbidity and mortality by age are similar in women and men. Methods: We included 37,545 women and 32,497 men from the Copenhagen General Population Study. Results: Plasma lipoprotein(a) increased with age, and in women we found an additional increase around age 50 (age by sex interaction p = 8∙10−7). In women, levels were 27% higher after menopause (p = 4∙10−61) and 12% lower during hormone replacement therapy (p = 2∙10−19). Adjustment for estimated Glomerular Filtration Rate in both sexes and plasma estradiol in women resulted in attenuated sex differences in lipoprotein(a) levels. In sex and age stratified multivariable adjusted models, lipoprotein(a) >40 mg/dL(83 nmol/L) versus <10 mg/dL(18 nmol/L) was associated with increased risk of myocardial infarction, ischemic heart disease, aortic valve stenosis, and heart failure (men only), but not statistically significant with risk of ischemic stroke, cardiovascular mortality, or all-cause mortality. Conclusions: Lipoprotein(a) levels increased modestly around age 50 selectively in women; however, risk of morbidity and mortality for high lipoprotein(a) was similar in women and men above age 50. This implies that elevated lipoprotein(a) above age 50 is a relatively more common cardiovascular risk factor in women, pointing toward repeat measurements in women above age 50.

AB - Background and aims: Lipoprotein(a) is a well-known causal risk factor for cardiovascular morbidity and mortality. Little is known about the effect of age and sex on lipoprotein(a) levels, and it is largely unknown if the same elevation in lipoprotein(a) confers the same increase in risk in women and men. We investigated whether lipoprotein(a) levels and lipoprotein(a) associated risks of morbidity and mortality by age are similar in women and men. Methods: We included 37,545 women and 32,497 men from the Copenhagen General Population Study. Results: Plasma lipoprotein(a) increased with age, and in women we found an additional increase around age 50 (age by sex interaction p = 8∙10−7). In women, levels were 27% higher after menopause (p = 4∙10−61) and 12% lower during hormone replacement therapy (p = 2∙10−19). Adjustment for estimated Glomerular Filtration Rate in both sexes and plasma estradiol in women resulted in attenuated sex differences in lipoprotein(a) levels. In sex and age stratified multivariable adjusted models, lipoprotein(a) >40 mg/dL(83 nmol/L) versus <10 mg/dL(18 nmol/L) was associated with increased risk of myocardial infarction, ischemic heart disease, aortic valve stenosis, and heart failure (men only), but not statistically significant with risk of ischemic stroke, cardiovascular mortality, or all-cause mortality. Conclusions: Lipoprotein(a) levels increased modestly around age 50 selectively in women; however, risk of morbidity and mortality for high lipoprotein(a) was similar in women and men above age 50. This implies that elevated lipoprotein(a) above age 50 is a relatively more common cardiovascular risk factor in women, pointing toward repeat measurements in women above age 50.

KW - Cardiovascular disease

KW - Death

KW - Hormone replacement therapy

KW - Lipids

KW - Lipoprotein(a)

KW - Sex differences

U2 - 10.1016/j.atherosclerosis.2022.06.1023

DO - 10.1016/j.atherosclerosis.2022.06.1023

M3 - Journal article

C2 - 35803767

AN - SCOPUS:85133683858

VL - 355

SP - 76

EP - 82

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -

ID: 321708841